We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The court ruled that the state “met its burden” in proving that J&J’s misleading marketing and promotion of opioids caused the state’s incurred costs. Read More
The U.S. Patent Trial and Appeal Board (PTAB) has decided to conduct an inter partes review of Opiant Pharmaceutical’s patent covering its opioid-overdose treatment Narcan (naloxone). Read More
A federal court in Delaware invalidated two of Amgen’s patents for the cholesterol drug Repatha (evolocumab), siding with Sanofi and Regeneron. Read More
A federal appeals court ruled that Praxair could not have infringed on five Mallinckrodt patents for inhaled nitric oxide because the patents were invalid. Read More